{"filings":[{"id":1481116,"accession_number":"0001753926-26-001144","cik":1266806,"company_name":"Vivani Medical, Inc.","ticker":"VANI","form_type":"8-K","filed_at":"2026-07-07T11:46:22+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Vivani subsidiary Cortigent to merge into ClearOne in stock deal; Novo Nordisk to evaluate semaglutide implant","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Cortigent (Vivani subsidiary) to merge into ClearOne (Nasdaq: CLRO) for 12.5M ClearOne shares; Vivani will control combined board.","ClearOne to raise $10M-$15M via unit offering as condition to close; closing expected by Dec 28, 2026.","Vivani enters non-exclusive agreement with Novo Nordisk to evaluate NPM-139 semaglutide implant for chronic weight management.","Phase 1 first-in-human study of NPM-139 expected mid-2026 with Wegovy as active comparator.","Lock-up: 50% of Vivani's ClearOne shares locked 1 year, 50% locked 2 years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":99170000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1342877,"accession_number":"0001753926-26-001109","cik":1266806,"company_name":"Vivani Medical, Inc.","ticker":"VANI","form_type":"8-K","filed_at":"2026-06-30T12:03:55+00:00","items":["5.02","5.07","8.01","9.01"],"status":"ready","headline":"Vivani Medical receives HREC approval to initiate Phase 1 trial of NPM-139 semaglutide implant for obesity","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received approval from Bellberry HREC in Australia to start SLIM-1 Phase 1 trial of NPM-139 semaglutide implant.","SLIM-1 trial initiation expected mid-2026; builds on prior Phase 1 success with NPM-119 exenatide implant in 2025.","Company plans SLIM-2 dose-ranging efficacy trial pending SLIM-1 results to accelerate NPM-139 development.","CEO cites strong market demand for miniature, reversible GLP-1 implant technology."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":99170000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":843156,"accession_number":"0001753926-26-000974","cik":1266806,"company_name":"Vivani Medical, Inc.","ticker":"VANI","form_type":"8-K","filed_at":"2026-06-04T11:30:48+00:00","items":["7.01","9.01"],"status":"ready","headline":"Vivani Medical to present at Jefferies conference; no new financial data disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["CEO Dr. Adam Mendelsohn to present at Jefferies Global Healthcare Conference on June 4, 2026.","Presentation materials furnished as Exhibit 99.1, but content not provided in the filing text.","No material operational or financial updates included beyond the presentation schedule."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":99170000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":68881,"accession_number":"0001753926-26-000854","cik":1266806,"company_name":"Vivani Medical, Inc.","ticker":"VANI","form_type":"8-K","filed_at":"2026-05-13T20:25:45+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Vivani Medical reports Q1 2026 net loss of $6.8M; SLIM-1 trial on track for mid-2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $6.8M in Q1 2026, up from $6.3M in Q1 2025; R&D expense $4.4M (+4% YoY).","Cash, equivalents and capital commitments of $28M expected to fund operations through first half of 2027.","Raised $9.7M in financing in Q1 2026, including $2.2M from a registered direct offering.","SLIM-1 Phase 1 trial of NPM-139 semaglutide implant to start mid-2026; top-line results by end of 2026.","Cortigent spin-off or IPO under consideration; S-1 amendment filed May 13, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":99170000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102187,"accession_number":"0001753926-26-000550","cik":1266806,"company_name":"Vivani Medical, Inc.","ticker":"VANI","form_type":"8-K","filed_at":"2026-03-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vivani Medical reports FY2025 net loss $26.6M; advances semaglutide implant NPM-139 towards Phase 1","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2025 net loss $26.6M vs $23.5M in FY2024; R&D expenses $18.1M up 15% YoY.","Cash $16.2M as of Dec 31, 2025; raised $41.5M gross from financings; funds ops into mid-2027.","Successful LIBERATE-1 first-in-human study; preclinical data shows >20% sham-adjusted weight loss for full year with single semaglutide implant.","Phase 1 study of NPM-139 (semaglutide implant) for chronic weight management expected mid-2026 with results by end of 2026.","Exploring spin-off or IPO of subsidiary Cortigent (neuromodulation assets)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":99170000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102186,"accession_number":"0001753926-26-000194","cik":1266806,"company_name":"Vivani Medical, Inc.","ticker":"VANI","form_type":"8-K","filed_at":"2026-01-27T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Vivani Medical prices $4.5M common stock offering; Chairman participates in private placement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $4.5M from registered direct offering (1.69M shares) and private placement (1.35M shares) at $1.48/share.","Chairman Gregg Williams purchased 1,351,351 shares in private placement at same price.","Net proceeds to fund clinical development and working capital; offering expected to close Jan. 27, 2026.","ThinkEquity acted as sole placement agent for the registered direct offering."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":99170000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118507,"accession_number":"0001753926-25-001768","cik":1266806,"company_name":"Vivani Medical, Inc.","ticker":"VANI","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Vivani Medical Q3 net loss $6.5M; plans Phase 1 semaglutide implant study in H1 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $6.5M in Q3 2025 vs $6.0M in Q3 2024; cash down to $4.0M from $19.7M at year-end 2024.","Closed ~$15.7M in October equity financings and $10M August private placement, total $25.7M cash and commitments.","Plans to initiate Phase 1 clinical study of NPM-139 semaglutide implant for chronic weight management in first half 2026.","Spin-off of Cortigent temporarily withdrawn due to U.S. government shutdown; new record date expected after SEC resumes.","R&D expense $4.5M ($4.2M in Q3 2024); G&A $2.2M ($2.1M in Q3 2024); operating expenses increased $0.4M."],"consensus_eps_estimate":-0.1122,"consensus_eps_actual":-0.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":99170000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118506,"accession_number":"0001753926-25-001655","cik":1266806,"company_name":"Vivani Medical, Inc.","ticker":"VANI","form_type":"8-K","filed_at":"2025-10-28T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Vivani Medical prices $15.7M equity offering; Chairman participates in $6.0M private placement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Registered direct offering of 6M shares and private placement of 3.7M shares priced at $1.62/share for total gross proceeds of ~$15.7M.","Private placement purchased by Board Chairman Gregg Williams, generating ~$6.0M; no warrants or fees incurred.","ThinkEquity acts as sole placement agent; Company to pay 7% fee plus up to $125k reimbursable expenses.","Closing expected October 28, 2025; proceeds to fund clinical development and working capital; officers subject to 60-day lock-up."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":99170000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118505,"accession_number":"0001753926-25-001582","cik":1266806,"company_name":"Vivani Medical, Inc.","ticker":"VANI","form_type":"8-K","filed_at":"2025-10-03T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Vivani Medical withdraws Cortigent spin-off record date due to US government shutdown","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Withdrew record date of October 8, 2025 for proposed spin-off of Cortigent subsidiary.","Delay caused by current shutdown of the U.S. federal government.","Company expects to reestablish and announce a new record date as soon as possible.","ThinkEquity is exclusive financial advisor to Cortigent for the spin-off transaction.","Cortigent develops brain implant devices with neuromodulation technology."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":99170000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134962,"accession_number":"0001753926-25-001510","cik":1266806,"company_name":"Vivani Medical, Inc.","ticker":"VANI","form_type":"8-K","filed_at":"2025-09-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vivani sets Oct 8 record date for Cortigent spin-off; Cortigent to trade as CRGT","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Record date for Cortigent spin-off is October 8, 2025; distribution date and ratio to be announced later.","Spin-off expected to complete by late-2025; Cortigent will trade on Nasdaq under ticker CRGT.","Cortigent develops brain implants (Orion vision system, stroke recovery device); has completed 6-year feasibility study.","Post spin-off, Vivani focuses on ultra long-acting GLP-1 implants for weight loss and type 2 diabetes.","Management teams will each focus on their respective strategies; Cortigent CEO Jonathan Adams to stay on."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":99170000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134961,"accession_number":"0001753926-25-001443","cik":1266806,"company_name":"Vivani Medical, Inc.","ticker":"VANI","form_type":"8-K","filed_at":"2025-09-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Vivani Medical files corporate slides; no specific material changes apparent from filing text","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Corporate slide presentation filed as Exhibit 99.1, date-stamped September 9, 2025.","Presentation posted on company website under 'Investors' section.","No financial results, product updates, or milestones cited in the 8-K text.","Slides speak as of filing date; company disclaims update obligation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":99170000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134960,"accession_number":"0001753926-25-001431","cik":1266806,"company_name":"Vivani Medical, Inc.","ticker":"VANI","form_type":"8-K","filed_at":"2025-09-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vivani Medical plans Phase 1/2 trials for NPM-139 semaglutide implant; H1 2026 start","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["NPM-139 is a semaglutide implant for chronic weight management in obese/overweight patients.","Phase 1 study expected to start H1 2026 pending regulatory clearance; designed for safety, tolerability, PK.","Phase 2 dose-ranging study planned to follow Phase 1, pending enabling results and regulatory feedback.","NPM-139 aims to deliver Wegovy-level efficacy with once or twice-yearly administration.","Positive preclinical data and promising LIBERATE-1 results for NPM-115 (exenatide) support program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":99170000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134959,"accession_number":"0001753926-25-001328","cik":1266806,"company_name":"Vivani Medical, Inc.","ticker":"VANI","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["1.01","2.02","3.02","7.01","8.01","9.01"],"status":"ready","headline":"Vivani Medical raises $10M, reports Q2 loss of $7.1M, advances semaglutide implant NPM-139","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Raised $10M via private placement of 7.94M shares at $1.26/share with director-affiliated entity.","Q2 2025 net loss $7.1M vs $5.3M in Q2 2024; cash $8.1M as of June 30, 2025.","Positive preclinical data for NPM-139: ~20% weight loss maintained >6 months with single implant.","Plans to initiate NPM-139 clinical program in 2026; spin off Cortigent division in H2 2025.","Appointed Anthony Baldor as CFO; additional $21.25M committed capital through July 2026."],"consensus_eps_estimate":-0.102,"consensus_eps_actual":-0.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":99170000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134958,"accession_number":"0001753926-25-001228","cik":1266806,"company_name":"Vivani Medical, Inc.","ticker":"VANI","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"Vivani Medical reports positive Phase 1 data for NPM-115 implant and prioritizes semaglutide implant NPM-139","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary Q2 2025 cash and cash equivalents $6.8M, plus $11.25M committed capital through March 2026.","LIBERATE-1 Phase 1 study of NPM-115 (exenatide implant) met primary safety and PK objectives; no serious adverse events.","Preclinical data for NPM-139 (semaglutide implant) showed ~20% weight loss maintained over 231 days from a single implant.","Vivani prioritizes NPM-139 for clinical development, with IND submission planned and clinical start expected in 2026.","Semaglutide products (Ozempic, Wegovy, Rybelsus) generated over $29B in 2024 sales, supporting prioritization."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":99170000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151906,"accession_number":"0001753926-25-001005","cik":1266806,"company_name":"Vivani Medical, Inc.","ticker":"VANI","form_type":"8-K","filed_at":"2025-06-25T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Vivani Medical stockholders elect board, ratify auditor, approve say-on-pay at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected all six director nominees: Gregg Williams, Aaron Mendelsohn, Dean Baker, Alexandra Popoff, Adam Mendelsohn, Daniel Bradbury.","Ratified BPM LLP as independent auditor for FY 2025, with 36.5M votes for, 98K against.","Advisory vote approved named executive officer compensation, with 23.1M for, 594K against, and 1.7M abstentions.","A quorum of 37.1M shares out of 59.2M outstanding was represented at the June 24, 2025 meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":99170000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151905,"accession_number":"0001753926-25-000966","cik":1266806,"company_name":"Vivani Medical, Inc.","ticker":"VANI","form_type":"8-K","filed_at":"2025-06-17T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Vivani Medical reports exenatide implant cuts liver fat 82% in obese mice","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exenatide implant reduced liver fat by 82% vs sham in high-fat diet obese mice after 12 weeks (Oil Red O staining).","Exenatide delivered via NanoPortal technology showed durable body weight reduction in rats over 105-140 days.","Findings from corporate slide presentation furnished as Exhibit 99.1; no material financial updates.","Vivani is developing NPM-119 (exenatide implant) for metabolic indications."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":99170000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151904,"accession_number":"0001753926-25-000956","cik":1266806,"company_name":"Vivani Medical, Inc.","ticker":"VANI","form_type":"8-K","filed_at":"2025-06-11T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Vivani Medical appoints Anthony Baldor as CFO, Brigid Makes resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Brigid Makes resigns effective June 15, 2025; no disagreement with company.","Anthony Baldor appointed CFO, Principal Financial Officer and Principal Accounting Officer effective June 15, 2025.","Baldor previously CFO at Diakonos Oncology and VP at 4D Molecular Therapeutics.","Baldor receives $450,000 base salary, performance bonus, and option for 600,000 shares vesting over 4 years.","Makes will serve in advisory capacity during transition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":99170000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151903,"accession_number":"0001753926-25-000898","cik":1266806,"company_name":"Vivani Medical, Inc.","ticker":"VANI","form_type":"8-K","filed_at":"2025-05-29T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vivani Medical files Form 10 for spin-off of Cortigent; expects Nasdaq listing in Q3 2025","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Cortigent files Form 10 to spin off from Vivani as independent Nasdaq company; completion expected Q3 2025.","Orion Visual Cortical Prosthesis completed Early Feasibility Study in March 2025; has FDA Breakthrough Device designation.","Cortigent advancing Stroke Recovery System to improve arm/hand movement recovery after stroke paralysis.","Vivani will focus solely on NanoPortal GLP-1 implants for chronic weight management and type 2 diabetes.","Spin-off requires final board approval, tax opinion, and SEC/Nasdaq clearance; shares distributed to Vivani stockholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":99170000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151902,"accession_number":"0001753926-25-000792","cik":1266806,"company_name":"Vivani Medical, Inc.","ticker":"VANI","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["1.01","2.02","3.02","7.01","8.01","9.01"],"status":"ready","headline":"Vivani Medical Q1 net loss $6.3M; secures $3M private placement; LIBERATE-1 data mid-2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 net loss of $6.3M (vs $6.0M prior year); cash, equivalents & restricted cash $14.3M as of March 31.","Announced $3.0M private placement with Chairman Gregg Williams entity at $1.03/share (2.9M shares).","LIBERATE-1 Phase 1 study on track; all NPM-115 (exenatide) implant insertions successful; top-line results mid-2025.","Promising preclinical data for NPM-139 semaglutide implant for chronic weight management in obese/overweight.","Plans to spin off Cortigent brain implant division as an independent publicly traded company."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":99170000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151901,"accession_number":"0001753926-25-000635","cik":1266806,"company_name":"Vivani Medical, Inc.","ticker":"VANI","form_type":"8-K","filed_at":"2025-04-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vivani Medical expands OKV-119 collaboration with Okava to include dogs for metabolic health","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Collaboration expanded to develop OKV-119 (long-acting GLP-1 implant) for dogs for weight management and diabetes.","Over 50% of U.S. dogs are overweight or obese; leaner dogs can live more than two years longer.","OKV-119 leverages NanoPortal technology for six-month+ dosing, mimicking fasting effects to improve insulin sensitivity.","Financial terms not disclosed; partnership minimizes Vivani's costs/risks with upside via milestone payments and royalties.","Expands prior 2019 collaboration that focused on developing OKV-119 for cats."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":99170000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170763,"accession_number":"0001753926-25-000526","cik":1266806,"company_name":"Vivani Medical, Inc.","ticker":"VANI","form_type":"8-K","filed_at":"2025-03-31T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Vivani Medical reports FY2024 net loss $23.5M; obesity implant trials on track for mid-2025 data","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2024 net loss $23.5M vs $25.7M YoY; cash $19.7M at Dec 31, 2024.","LIBERATE-1 (NPM-115 exenatide) fully enrolled; top-line data expected mid-2025.","NPM-139 (semaglutide) preclinical data positive, once-yearly dosing potential.","Closed $8.25M equity financing on March 27, 2025 to fund into Q2 2026.","Plans to spin off Cortigent subsidiary as independent public company."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":99170000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170762,"accession_number":"0001753926-25-000495","cik":1266806,"company_name":"Vivani Medical, Inc.","ticker":"VANI","form_type":"8-K","filed_at":"2025-03-27T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Vivani Medical raises $8.25M in private placement led by Chairman; extends cash runway into Q2 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 7,366,071 shares at $1.12 each to an entity beneficially owned by Chairman Gregg Williams.","Gross proceeds of ~$8.25M; no warrants, discounts, or placement agent fees incurred.","Funding expected to extend cash runway into Q2 2026 and accelerate NPM-139 (semaglutide) implant development.","Placement occurs over multiple closings through January 15, 2026, under Rule 506/Regulation D."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":99170000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170761,"accession_number":"0001753926-25-000488","cik":1266806,"company_name":"Vivani Medical, Inc.","ticker":"VANI","form_type":"8-K","filed_at":"2025-03-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vivani Medical Reports Positive Preclinical Data for Once-Yearly Semaglutide Implant NPM-139","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["NPM-139 treatment resulted in nearly 20% placebo-adjusted weight loss from a single administration in healthy rats over 91 days.","Data show smooth, non-fluctuating in vivo release and continuous semaglutide exposure, supporting potential for once or twice-yearly dosing.","Vivani's proprietary NanoPortal technology demonstrated versatility beyond exenatide implant NPM-115, with in vitro stability over one year.","First-in-human study LIBERATE-1 for NPM-115 remains on track for top-line data by mid-2025, providing critical information for NPM-139."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":99170000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170760,"accession_number":"0001753926-25-000438","cik":1266806,"company_name":"Vivani Medical, Inc.","ticker":"VANI","form_type":"8-K","filed_at":"2025-03-13T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"Vivani plans Cortigent spin-off, reports $18.4M cash; LIBERATE-1 trial fully enrolled with first implant","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Spin-off of Cortigent into independent public company planned by mid-2025; expects tax-free distribution to Vivani shareholders.","Cortigent's Orion artificial vision device completed 6-year study; Argus II previously FDA-authorized for blindness.","LIBERATE-1 trial of GLP-1 implant NPM-115: first implant administered, all 24 subjects enrolled in 4 weeks; top-line data expected mid-2025.","Preliminary cash and cash equivalents (excluding restricted) as of Dec 31, 2024: $18.4M (unaudited).","ThinkEquity LLC acting as financial advisor to Cortigent for spin-off."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":99170000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187729,"accession_number":"0001753926-24-001872","cik":1266806,"company_name":"Vivani Medical, Inc.","ticker":"VANI","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Vivani Medical Q3 net loss $6.0M; $5M equity financing; GLP-1 implant study approved in Australia","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $6.0M for Q3 2024 vs $6.8M YoY; cash $21.0M as of Sept 30, 2024.","Regulatory approval in Australia for LIBERATE-1 Phase 1 trial of GLP-1 (exenatide) implant in obese/overweight patients.","Private sale of 3.97M shares at $1.26/share to a director for $5.0M gross proceeds, extending runway into late 2025.","Preclinical data: 82% sham-implant adjusted liver fat reduction and 20% weight loss comparable to semaglutide.","R&D expense $4.2M (-5% YoY); G&A $2.1M (-22% YoY); operating expenses decreased $0.8M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":99170000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187728,"accession_number":"0001753926-24-001731","cik":1266806,"company_name":"Vivani Medical, Inc.","ticker":"VANI","form_type":"8-K","filed_at":"2024-10-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vivani Medical to present at PODD and ThinkEquity conferences in late October 2024","summary_kind":"llm","event_type":"other","confidence":"medium","bullets":["CEO Dr. Adam Mendelsohn to speak on a PODD panel on Oct 29 in Boston.","Mendelsohn will also present a company update at ThinkEquity Conference on Oct 30 in New York.","No financial data or material corporate developments disclosed in the announcement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":99170000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204233,"accession_number":"0001753926-24-001628","cik":1266806,"company_name":"Vivani Medical, Inc.","ticker":"VANI","form_type":"8-K","filed_at":"2024-09-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vivani Medical gets Australian approval to start first-in-human GLP-1 implant trial LIBERATE-1","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Approval from Bellberry HREC and TGA acknowledgement for LIBERATE-1 trial in obese/overweight subjects.","Trial will evaluate safety, tolerability, and PK of exenatide NanoPortal implant in 24 participants.","Preclinical data suggests comparable efficacy to semaglutide with twice-yearly dosing.","Enrollment expected Q4 2024; data projected in 2025; Australian R&D incentives may defray costs.","Data intended to support regulatory submissions in the US and other geographies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":99170000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204232,"accession_number":"0001753926-24-001614","cik":1266806,"company_name":"Vivani Medical, Inc.","ticker":"VANI","form_type":"8-K","filed_at":"2024-09-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vivani Medical to present at Emerging Growth Conference on Sept 25, 2024","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["CEO Adam Mendelsohn will deliver a company overview at 1:10 PM ET on September 25.","Investors can register for the interactive webcast and submit questions in advance.","An archived webcast will be available on EmergingGrowth.com and YouTube afterward."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":99170000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204231,"accession_number":"0001753926-24-001531","cik":1266806,"company_name":"Vivani Medical, Inc.","ticker":"VANI","form_type":"8-K","filed_at":"2024-09-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vivani Medical reports 82% sham-adjusted liver fat reduction with GLP-1 implant","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sham-implant adjusted liver fat reduction of 82% in obese mouse model from single administration with twice-yearly dosing.","Previously reported 20% sham-implant adjusted weight loss, comparable to semaglutide arm.","Clinical development for NPM-115 program (exenatide implant) in overweight/obese patients on track for Q4 2024 start in Australia.","LIBERATE-1 first-in-human study expected to start Q4 2024 with data in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":99170000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204230,"accession_number":"0001753926-24-001422","cik":1266806,"company_name":"Vivani Medical, Inc.","ticker":"VANI","form_type":"8-K","filed_at":"2024-08-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Vivani Medical reports Q2 net loss $5.3M; cash $26.3M; NPM-115 FIH study expected Q4 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $26.3M as of June 30, 2024 ($31.0M at March 31, 2024); enough to fund operations into H2 2025.","Net loss $5.3M vs $6.5M YoY; R&D expense $3.5M (-9% YoY), G&A $2.2M (-31% YoY).","FDA cleared IND for NPM-119 (six-month GLP-1 implant for type 2 diabetes) in June 2024.","First-in-human LIBERATE-1 study for NPM-115 (obesity implant) expected to start Q4 2024 in Australia, data in 2025.","Veterinary GLP-1 implant data published in BMC Veterinary Research; 40% of domestic cats overweight."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":99170000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204229,"accession_number":"0001753926-24-001236","cik":1266806,"company_name":"Vivani Medical, Inc.","ticker":"VANI","form_type":"8-K","filed_at":"2024-07-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vivani to start LIBERATE-1 study of GLP-1 implant for obesity in Q4 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["NPM-115 is a 6-month exenatide implant for chronic weight management in obese/overweight patients.","LIBERATE-1: 24 patients randomized to implant, Bydureon BCise, or semaglutide for 9 weeks.","Study expected to begin Q4 2024 in Australia; data projected in 2025.","FDA cleared IND for NPM-119 (type 2 diabetes) in June 2024; company prioritized NPM-115.","Company plans to use Australian R&D incentives to defray trial costs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":99170000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220957,"accession_number":"0001753926-24-001171","cik":1266806,"company_name":"Vivani Medical, Inc.","ticker":"VANI","form_type":"8-K","filed_at":"2024-06-28T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Vivani Medical stockholders elect six directors, ratify auditor, approve say-on-pay","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected directors Gregg Williams, Aaron Mendelsohn, Dean Baker, Alexandra Larson, Adam Mendelsohn, Daniel Bradbury with >24M votes for each.","Ratified BPM LLP as independent auditor for FY2024: 34,974,648 for, 195,530 against, 62,383 abstained.","Approved non-binding advisory executive compensation vote: 22,484,128 for, 203,434 against, 1,646,753 abstained.","Quorum of 35,232,561 shares (64.1% of outstanding) represented at the June 27, 2024 meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":99170000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220956,"accession_number":"0001753926-24-001110","cik":1266806,"company_name":"Vivani Medical, Inc.","ticker":"VANI","form_type":"8-K","filed_at":"2024-06-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA lifts clinical hold on Vivani Medical's NPM-119, clears IND for Phase 1 trial","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA cleared IND and lifted clinical hold for NPM-119 (exenatide), a six-month GLP-1 implant for type 2 diabetes.","LIBERATE-1 Phase 1 trial will assess safety, tolerability, and pharmacokinetics vs. Bydureon BCise; enrollment expected H2 2024.","First clinical application of NanoPortal implant technology; addresses medication non-adherence affecting ~50% of type 2 diabetes patients.","Lead program NPM-115 (high-dose exenatide) for chronic weight management showed preclinical weight loss comparable to semaglutide.","NPM-139 (semaglutide implant) in pipeline with potential once-yearly dosing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":99170000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220955,"accession_number":"0001753926-24-000957","cik":1266806,"company_name":"Vivani Medical, Inc.","ticker":"VANI","form_type":"8-K","filed_at":"2024-05-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Vivani Medical Q1 net loss $6.0M, cash $31.0M; NPM-115 IND on track for H2 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $6.0M in Q1 2024 vs $6.3M in Q1 2023; cash $31.0M at March 31, 2024, up from $22.0M.","Completed $15M registered direct offering in March 2024, extending cash runway into H2 2025.","NPM-115 IND submission on track for H2 2024; first-in-human trial planned after regulatory clearance.","Positive preclinical data: NPM-115 showed ~20% weight loss in mice, comparable to semaglutide.","Appointed Daniel Bradbury to Board; he led Amylin's development of first once-weekly GLP-1 Bydureon."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":99170000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220954,"accession_number":"0001753926-24-000816","cik":1266806,"company_name":"Vivani Medical, Inc.","ticker":"VANI","form_type":"8-K","filed_at":"2024-04-23T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Vivani Medical enters into $75M ATM equity offering agreement with Jefferies LLC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Up to $75M of common stock may be sold at-the-market through Jefferies as sales agent.","Company pays Jefferies commission of up to 3% of gross proceeds; no obligation to sell.","ATM facility provides financing flexibility; proceeds intended for general corporate purposes.","Shares offered under a new S-3 shelf registration statement filed on April 22, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":99170000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240555,"accession_number":"0001753926-24-000612","cik":1266806,"company_name":"Vivani Medical, Inc.","ticker":"VANI","form_type":"8-K","filed_at":"2024-03-26T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Vivani Medical shifts focus to GLP-1 obesity implants; Q4 net loss $6.0M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $22.0M as of Dec 31, 2023, down from $46.4M; $15M March 2024 financing extends runway into H2 2025.","Full-year 2023 net loss $25.7M vs $13.9M in 2022; R&D expenses rose 20% to $17.0M.","Positive preclinical data: NPM-115 (exenatide) showed ~20% weight loss in obese mice, comparable to semaglutide.","Daniel Bradbury appointed to Board; led Amylin's approval of once-weekly GLP-1 Bydureon.","Anticipates NPM-115 IND filing in H2 2024 and NPM-119 clinical hold response in H1 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":99170000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240554,"accession_number":"0001753926-24-000474","cik":1266806,"company_name":"Vivani Medical, Inc.","ticker":"VANI","form_type":"8-K","filed_at":"2024-03-06T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Vivani Medical appoints Daniel Bradbury to Board; former Amylin CEO led first once-weekly GLP-1 drug","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Daniel Bradbury appointed to board effective March 4, 2024, filling newly created vacancy expanding board from 5 to 6 members.","Bradbury was CEO of Amylin Pharmaceuticals until its $7.1B acquisition by Bristol-Myers Squibb in 2012; Amylin secured first once-weekly GLP-1 approval (Bydureon).","He will serve on Audit Committee; annual retainers: $35,000 for board, $10,000 for committee.","His GLP-1 expertise aligns with Vivani's lead programs: six-month GLP-1 implants NPM-115 (obesity) and NPM-119 (type 2 diabetes)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":99170000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240553,"accession_number":"0001753926-24-000466","cik":1266806,"company_name":"Vivani Medical, Inc.","ticker":"VANI","form_type":"8-K","filed_at":"2024-03-05T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Vivani Medical prices $15M registered direct offering of 3.95M shares and warrants at $3.80","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offers 3,947,368 shares of common stock and warrants to purchase same amount; gross proceeds ~$15.0M.","Warrants exercisable at $3.80/share immediately and expire three years from issuance.","Closing expected on or about March 5, 2024; Maxim Group is sole placement agent.","Directors and officers subject to 90-day lock-up; company has 45-day no-issuance commitment.","Preclinical-stage biopharma developing GLP-1 implants; proceeds for general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":99170000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240552,"accession_number":"0001753926-24-000411","cik":1266806,"company_name":"Vivani Medical, Inc.","ticker":"VANI","form_type":"8-K","filed_at":"2024-02-28T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Vivani reports NPM-115 preclinical weight loss comparable to Ozempic/Wegovy; prioritizes obesity","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["NPM-115 (exenatide implant) achieved ~20% weight loss in obese mice, similar to semaglutide injections.","Disclosed semaglutide as API in NPM-139, a once-yearly implant for chronic weight management.","Strategic shift to prioritize obesity implants; NPM-115 designed for twice-yearly dosing.","IND for NPM-119 (type 2 diabetes) on clinical hold; expects to submit CMC info to FDA in H1 2024.","Plans to submit IND for NPM-115 first-in-human obesity study later in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":99170000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240551,"accession_number":"0001753926-24-000087","cik":1266806,"company_name":"Vivani Medical, Inc.","ticker":"VANI","form_type":"8-K","filed_at":"2024-01-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vivani Medical regains compliance with Nasdaq minimum bid price rule","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq deficiency notice on Dec 26, 2023 for bid price below $1 for 30 consecutive days.","On Jan 9, 2024, Nasdaq confirmed compliance after 10 consecutive business days at $1 or above (Dec 22 to Jan 8).","Delisting risk removed; Nasdaq considers the matter closed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":99170000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":258059,"accession_number":"0001753926-23-001644","cik":1266806,"company_name":"Vivani Medical, Inc.","ticker":"VANI","form_type":"8-K","filed_at":"2023-12-27T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"Vivani Medical receives Nasdaq deficiency notice for bid price below $1.00","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Vivani on Dec 26, 2023 that common stock closed below $1.00 for 30 consecutive trading days through Dec 21, 2023.","Company has 180 days (until June 24, 2024) to regain compliance by maintaining $1.00 closing bid price for at least 10 consecutive trading days.","If not compliant by June 24, 2024, Vivani may be eligible for an additional 180-day period if it meets other listing standards and intends to cure (e.g., reverse stock split).","Failure to regain compliance could lead to delisting; Vivani may appeal any delisting determination to a Nasdaq Hearings Panel.","Vivani intends to monitor bid price and may consider actions including a reverse stock split, subject to board and stockholder approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":99170000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":258058,"accession_number":"0001753926-23-001534","cik":1266806,"company_name":"Vivani Medical, Inc.","ticker":"VANI","form_type":"8-K","filed_at":"2023-11-24T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Vivani Medical terminates named executive officer Scott Dunbar in subsidiary workforce reduction","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Scott Dunbar terminated without cause effective Nov 20, 2023 as part of Cortigent workforce reduction.","Dunbar was a named executive officer in 2023 proxy and former Acting CEO of predecessor Second Sight Medical.","Severance includes ~$70,000 cash payment and COBRA premium reimbursement for up to six months.","Company intends to enter a separation and release agreement with Dunbar."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":99170000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":258057,"accession_number":"0001753926-23-001482","cik":1266806,"company_name":"Vivani Medical, Inc.","ticker":"VANI","form_type":"8-K","filed_at":"2023-11-14T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Vivani Medical Q3 net loss $6.8M; adds NPM-115 for weight management","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $6.8M in Q3 2023 vs net income of $1.4M in Q3 2022, driven by prior-year bargain purchase gain.","Cash and equivalents $26.2M at Sept 30, 2023; expected to fund operations into early 2025.","Announced NPM-115 (high-dose exenatide implant) for chronic weight management in obese/overweight patients.","FDA clinical hold on NPM-119 FIH study due to CMC requests; also planning FIH study in Australia.","R&D expense $4.4M (+15% YoY); G&A expense $2.7M (+71% YoY) due to merger-related costs."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.39,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":99170000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275372,"accession_number":"0001753926-23-001239","cik":1266806,"company_name":"Vivani Medical, Inc.","ticker":"VANI","form_type":"8-K","filed_at":"2023-09-18T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Vivani Medical provides update on FDA clinical hold for NPM-119 diabetes implant","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA placed full clinical hold on NPM-119 Phase 2a LIBERATE-1 study on Aug 18, 2023, due to CMC deficiencies.","Second complete response submitted Sept 15, 2023; FDA has 30 days to respond.","If hold lifted, trial start in 2023, interim data 1H2024, full top-line 2H2024.","If response deemed inadequate, Vivani will provide updated guidance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":99170000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275371,"accession_number":"0001753926-23-001153","cik":1266806,"company_name":"Vivani Medical, Inc.","ticker":"VANI","form_type":"8-K","filed_at":"2023-08-29T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Vivani's NPM-119 trial on clinical hold; submits Complete Response to FDA","summary_kind":"llm","event_type":"regulatory","confidence":"medium","bullets":["FDA placed LIBERATE-1 study on clinical hold Aug 11, citing insufficient CMC information to assess human subject risks.","Vivani submitted Complete Response on Aug 25; FDA has 30 days to respond.","If hold lifted, Phase 2a trial expected to start Oct 2023, interim results 1H2024, top-line 2H2024.","If CR inadequate, timeline delayed by ~one quarter.","Cortigent subsidiary to repay $1.5M and issue $2M promissory note at 5% under amended funding agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":99170000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275370,"accession_number":"0001753926-23-000914","cik":1266806,"company_name":"Vivani Medical, Inc.","ticker":"VANI","form_type":"8-K","filed_at":"2023-07-10T23:59:59+00:00","items":["3.03","5.03","8.01","9.01"],"status":"ready","headline":"Vivani Medical reincorporates from California to Delaware effective July 5, 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reincorporation approved at June 15, 2023 Annual Meeting; Plan of Conversion effective July 5, 2023.","Each California common share converted into one Delaware common share; trading symbol VANI unchanged.","Stockholder rights now under Delaware law, Certificate of Incorporation, and new Bylaws.","No change in business, headquarters, management, or jobs; directors and officers continue.","Authorized capital: 300M shares common ($0.0001 par) and 10M shares undesignated preferred."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":99170000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":292850,"accession_number":"0001753926-23-000806","cik":1266806,"company_name":"Vivani Medical, Inc.","ticker":"VANI","form_type":"8-K","filed_at":"2023-06-16T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Vivani Medical shareholders approve reincorporation to Delaware and governance changes at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All five director nominees elected with >=98% of votes cast: Gregg Williams, Aaron Mendelsohn, Dean Baker, Alexandra Larson, Adam Mendelsohn.","Ratification of BPM as independent auditor for FY2023 approved: 35,330,026 for, 73,358 against, 145,310 abstain.","Reincorporation from California to Delaware approved: 28,968,542 for, 103,485 against, 5,614 abstain.","Charter provisions approved: eliminating cumulative voting, limiting director removal without cause, board-only special meetings, and no action by written consent.","Exclusive forum provisions for intra-corporate and Securities Act claims approved; advisory vote on executive compensation also passed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":99170000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":292849,"accession_number":"0001753926-23-000657","cik":1266806,"company_name":"Vivani Medical, Inc.","ticker":"VANI","form_type":"8-K","filed_at":"2023-05-15T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Vivani Medical Q1 net loss $6.3M; maintains IND filing timeline for NPM-119","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $38.1M at March 31, 2023, down from $45.1M; sufficient to fund operations into H2 2024.","R&D expense $4.0M (+48% YoY); operating expenses $6.6M (+69% YoY) driven by Second Sight acquisition costs.","Net loss $6.3M vs $3.9M in Q1 2022; increase due to $2.7M higher operating expenses.","Plans to file NPM-119 IND with FDA by mid-2023; if cleared, initiate LIBERATE-1 trial in Q3 2023 with top-line data in H1 2024.","Expects to complete Cortigent IPO in Q3 2023; Vivani to retain control after offering."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":99170000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":313512,"accession_number":"0001753926-23-000298","cik":1266806,"company_name":"Vivani Medical, Inc.","ticker":"VANI","form_type":"8-K","filed_at":"2023-03-21T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Vivani Medical subsidiary Cortigent files for IPO; Vivani to fund ops until offering","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cortigent, Vivani's neuromodulation subsidiary, filed S-1 for IPO; ThinkEquity sole book-runner.","Vivani agrees to fund Cortigent salaries, rent, overhead until Dec 31, 2024 or IPO close.","Cortigent must repay all advanced funds plus accrued interest after funding support term.","Cortigent will be controlled by Vivani post-IPO, led by CEO Jonathan Adams.","IPO subject to market conditions; no assurance of completion or terms."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":99170000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":313511,"accession_number":"0001753926-23-000173","cik":1266806,"company_name":"Vivani Medical, Inc.","ticker":"VANI","form_type":"8-K","filed_at":"2023-02-17T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Vivani Medical releases updated corporate slide presentation; no specific financial or operational milestones disclosed.","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Slide deck provides business overview but lacks new specific numbers or targets.","No changes to financial guidance, pipeline updates, or capital structure mentioned.","Presentation posted on company website and furnished as an exhibit to the Form 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":99170000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-02-17T23:59:59+00:00|313511"}